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One criterion that places a patient at high risk is a previous neutropenic complication in the immediate previous cycle with no plan to reduce dose intensity. This table applies to prophylaxis for the first cycle of chemotherapy for solid tumors and non-myeloid malignancies.
. ingle temperature: 38.3°C orally or 38.0°C over 1 h; neutropenia: < 500 neutrophils/mcL or < 1,000 neutrophils/mcL and a predicted decline to 500/mcL over the next 48 h. .
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There are many factors that need to be evaluated to determine a patient's risk categorization; these include type of chemotherapy regimen ( ) and patient risk factors ( ). . g CSF= Colony stimulating factors h The confounding effects of anthracycline and alkylating agent dose, radiation dose and field size, and colony stimulating factors use on the slight excess risk of leukemia and MDS in patients treated with these agents and modalities are currently unquantified. The associated risk of leukemia and MDS has been suggested by epidemiologic studies, but has not been observed in the available prospective randomized studies. There is category 1 evidence for G-CSF for a reduction of: risk of febrile neutropenia, hospitalization, intravenous antibiotics during the course of therapy. There is category 2A evidence for G-CSF for a reduction in infection related mortality during the course of treatment. (See discussion for further detail.) Only consider CSF if patients are at significant risk for serious medical consequences of febrile neutropenia, including death. The use of CSF in this setting is a difficult decision and requires careful discussion between the physician and the patient. If patient risk factors determine the risk is10 -20%, CSF is reasonable. However, if the risk is due to the chemotherapy regimen, other alternatives such as the use of less myelosuppressive chemotherapy or dose reduction, if of comparable benefit, should be explored.
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SECONDARY PROPHYLAXIS
c Febrile neutropenia is defined as, single temperature: 38.3°C orally or 38.0°C over 1 h; neutropenia: < 500 neutrophils/mcL or < 1,000 neutrophils/mcL and a predicted decline to 500/mcL over the next 48 h. . Dose-limiting neutropenic event could be a nadir count or day of treatment count that may otherwise impact planned dose of chemotherapy. Febrile neutropenia is defined as, single temperature: 38.3°C orally or 38.0°C over 1 h; neutropenia: < 500 neutrophils/mcL or < 1,000 neutrophils/mcL and a predicted decline to 500/mcL over the next 48 h. . For antibiotic therapy recommendations for fever and neutropenia, . The decision to use CSF in the therapeutic setting is controversial. See discussion for further detail.
There are no studies which have addressed therapeutic use of filgrastim for febrile neutropenia in patients who have already received prophylactic pegfilgrastim. However, pharmacokinetic data of pegfilgrastim demonstrated high levels during neutropenia and suggests that additional CSF will not be beneficial.
here is no data on pegfilgrastim in therapeutic setting. Either filgrastim or sargramostim should be used with initial dosing as outlined on and discontinued at time of neutrophil recovery. 
PATIENT RISK FACTORS FOR DEVELOPING FEBRILE NEUTROPENIA
In addition to the risk of the chemotherapy regimen and the specific malignancy being treated, these factors need to be considered when evaluating a patient's overall risk for febrile neutropenia. There is evidence to support use for chemotherapy regimens given every 3 wks (category 1). Phase II studies demonstrate efficacy in chemotherapy regimens given every 2 wks. There are insufficient data to support dose and schedule of weekly regimens or chemotherapy schedules less than 2 weeks and these cannot be recommended.
Older patient, notably patients age 65 and older ( ) Previous chemotherapy or radiation therapy

(rounding to the nearest vial size by institution-defined weight limits). Start 24-72 h after completion of chemotherapy and treat through post-nadir recovery. Administration of growth factor on same day as chemotherapy is not recommended. concurrent chemotherapy and radiation
Prophylactic antibiotics are not routinely recommended for standard dose chemotherapy, . 1 Randomized phase II trials of pegfilgrastim administration the same day as chemotherapy versus administration the day after chemotherapy have shown an increase in febrile neutropenia and/or other adverse events. See discussion for details. 2 There is category 1 evidence to support filgrastim or pegfilgrastim for the prevention of febrile neutropenia. There is insufficient evidence for a category 1 recommendation for sargramostim in this setting. Sargramostim is indicated for use following induction chemotherapy in older adult patients with AML. Studies are ongoing in other areas.
Practice Guidelines in Oncology -v. Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.
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Category 2B:
The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).
Category 3:
The recommendation is based on any level of evidence but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.
Overview
Neutropenia (< 500 neutrophils/mcl or < 1,000 neutrophils/mcl and a predicted decline to ≤ 500/mcl over the next 48 h) and resulting febrile neutropenia (≥ 38.3°C orally or ≥ 38.0°C over 1 h) can be induced by myelosuppressive chemotherapy. Febrile neutropenia (FN) in turn is a major dose-limiting toxicity of chemotherapy, often requiring prolonged hospitalization and broad-spectrum antibiotic use (reviewed by Lyman and Kuderer When reported, the rates of myelosuppression with the same and similar regimens varied greatly, making it difficult to determine the actual risk for neutropenic complications associated with common chemotherapy regimens. 2 Differences in the reported rates of neutropenic complications may relate to differences in study patient populations as well as the delivered dose intensity. Treatment dose intensity was reported with even less consistency, making it very difficult to interpret differences in reported rates of toxicity or treatment efficacy.
A review by Dale et al showed that about 25-40% of treatment-naive patients develop FN with common chemotherapy regimens. 3 Occurrence of FN may delay subsequent chemotherapy courses or result in dose reduction that may compromise treatment outcomes. Development of FN also increases diagnostic and treatment costs and often leads to longer hospital stays. In addition, correlations have been reported between changes in neutrophil counts and quality of life, as measured by physical functioning, vitality, and mental health. 4 Filgrastim and pegfilgrastim, both granulocyte-colony stimulating factors (G-CSF), currently have FDA approval for use in the prevention of chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte-macrophage colony stimulating factor (GM-CSF), is limited to use following induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. It should be noted that recommendations are based on evidence derived mainly from studies on G-CSFs. There is a lack of head-to-head comparative studies on the clinical benefits of G-CSFs and GM-CSFs. 
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Benefits and Risks of CSFs
The prophylactic use of G-CSFs has been shown to reduce the incidence, length and severity of chemotherapy-related neutropenia in small cell lung cancer, breast cancer, sarcoma, and non-Hodgkin's lymphoma. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] G-CSFs also improved delivery of full dose intensity of chemotherapy at the planned schedule, although this has not been generally shown to lead to better response or higher overall survival. 5, 7, 9, [12] [13] [14] [15] 17, 18 However, in node-positive breast cancer 19 and aggressive lymphoma, 20 dose-dense regimens supported by G-CSFs improved disease-free and/or overall survival compared to conventional chemotherapy.
Meta-analyses have confirmed the efficacy of prophylactic CSFs in decreasing rates of infection, 21, 22 and risk of neutropenia. 21, 22 In a recent meta-analysis of seventeen randomized trials of prophylactic G-CSFs including 3493 adult patients with solid tumor and lymphoma, 23 G-CSF as primary prophylaxis reduces risk of FN (RR = 0.54; 95% CI, 0.43 to 0.67; P < 0.001) and improves relative dose-intensity of the chemotherapy delivered (average difference between study arms 8.4%; P = 0.001). For the first time, this analysis also reports a substantial reduction in risk of infection-related mortality (RR = 0.55; 95% CI, 0.33 to 0.90; P = 0.018) and all early deaths during chemotherapy (RR = 0.60; 95% CI, 0.43 to 0.83; P = 0.002).
Over the last decade, the costs of inpatient hospitalization have escalated, changing the risk threshold on a pure cost basis from 40% to approximately 20%. 24 Economic analyses of CSFs have yielded mixed results, depending on the context of usage. [25] [26] [27] [28] [29] However, the policy of the NCCN Myeloid Growth Factors guidelines panel is to look primarily at issues of therapeutic efficacy and clinical benefit, rather than cost.
The indication for prophylactic CSF use depends on the risk of FN or other neutropenic events that can potentially compromise treatment.
Toxicity risks associated with G-CSFs and GM-CSF, as outlined in the prescribing information, are listed on MGF-D. To date, the main consistently observed toxicity associated with G-CSF therapy was mild to moderate bone pain. 30 This is usually effectively controlled by nonnarcotic analgesics. The meta-analysis by Kuderer et al confirmed a heightened risk of musculoskeletal pain associated with CSF (RR = 4.03; 95% CI, 2.15 to 7.52; P < 0.001). 23 In a retrospective review, a heightened rate of bleomycin pulmonary toxicity has been linked to G-CSF use in Hodgkin's lymphoma patients receiving bleomycincontaining therapy. 31 This has not been seen with G-CSF use in bleomycin-containing testicular cancer chemotherapy regimens. 18 There have also been reports of rare cases of splenic rupture with G-CSF usage, some of which were fatal. 30 These cases occurred in patients and healthy donors in the stem cell transplantation setting. Some patients develop allergic reactions in the skin, the respiratory system, or the cardiovascular system (filgrastim only). Although there have been suggestions of potentially increased risk of acute leukemia with G-CSF administration from epidemiological studies, they are confounded by differences in the chemotherapy dose delivered. The Research on Adverse Drug Events and Reports (RADAR) group concluded that long-term safety data is still lacking to confirm such a relationship. and sixty five women received a placebo injection and 463 women received pegfilgrastim, each administered 24 hours after chemotherapy in a double blind study designed with FN as the primary endpoint. The placebo group had an overall incidence of FN of 17%. By contrast, the pegfilgrastim group had a 1% incidence. The incidence of hospitalization was reduced from 14% to 1%, and the use of IV antiinfectives was reduced from 10% to 2%, with all of these differences statistically significant (p<0.001). In cycle 1, there was an 11% rate of FN in the first cycle for the placebo group versus <1% in the pegfilgrastim group. For cycles 2 through 4, the placebo group had a 6% rate of FN with <1% in the pegfilgrastim group.
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A second trial reported the results of 175 patients with small cell lung cancer who were randomized to receive prophylactic antibiotics with or without prophylactic G-CSF. 6 In cycle 1, 20 patients (24%) in the antibiotics-only group developed FN compared with nine patients (10%) in the antibiotics plus FN group (P = 0.01). In cycles 2 to 5, the incidences of FN were similar in both groups (17% vs. 11%). The authors concluded that primary FN prophylaxis added to primary antibiotic prophylaxis is effective in reducing FN and infections in patients with small cell lung cancer with the first cycle of chemotherapy. Prophylactic CSF is recommended for any patient considered at high risk, regardless of whether the treatment is intended to be curative, to prolong survival or to manage symptoms.
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Patients at Intermediate Risk of FN
The NCCN panel defines intermediate risk as a 10-20% probability of developing FN or a neutropenic event that would compromise treatment. In all three categories of treatment intent, the panel recommends individualized consideration of CSF use based on physician-patient discussion of the risk-benefit ratio of the likelihood of developing FN, the potential consequences of a neutropenic event and the implications of reduced chemotherapy dose delivery. When the intent of chemotherapy is designed to prolong survival or for symptom management, the use of CSF is a difficult decision and requires careful discussion between the physician and patient. If patient risk factors determine the risk, CSF is reasonable. If the risk is due to the chemotherapy regimen, other alternatives such as the use of less myelosuppressive chemotherapy or dose reduction, if of comparable benefit, should be explored.
Patients at Low Risk of FN
For low-risk patients, as defined by a <10% risk, routine use of CSFs is not considered cost-effective and alternative treatment options are appropriate. 24, [34] [35] [36] However, CSFs may be considered if the patient is receiving curative or adjuvant treatment and is at significant risk for serious medical consequences of FN, including death.
Evaluation of Subsequent Chemotherapy Cycles (MGF-2)
After the first cycle, patient evaluation should be performed prior to each subsequent cycle to determine the risk categorization and treatment intent. If the patient experienced a previous episode of FN or a dose-limiting neutropenic event (a nadir or a day-of-treatment count impacting the planned dose of chemotherapy) during the previous cycle of treatment with the same dose and schedule planned for the current cycle, this patient is now in the high risk group.
If the patient experiences such an episode despite receiving CSF, the panel recommends a chemotherapy dose reduction or change in treatment regimen unless there is an impact on patient survival. If the patient does not develop FN or a dose-limiting neutropenic event and is thought to be benefiting from chemotherapy, the previous assessment should be repeated after each subsequent cycle.
Chemotherapy Regimens and Risk of FN (MGF-A)
The development of FN is a common dose-limiting toxicity of many single agents and combination chemotherapy regimens. This risk is directly related to the intensity of the chemotherapy regimen. As discussed above, chemotherapy regimens that have an incidence of FN greater than 20% in clinical trials in chemotherapy-naive patients are considered by the panel at 'high risk,' and CSF-prophylaxis is recommended. It should be noted that some regimens, such as the RICE and CHOP-14 regimen for non-Hodgkin's lymphoma have only been tested with growth factor support. Benefits of pegfilgrastim have not been shown in regimens given under a two-week duration. Pegfilgrastim should be avoided in patients receiving weekly chemotherapy. There has been controversy surrounding the use of G-CSFs for patients with Hodgkin's lymphoma undergoing bleomycin-containing chemotherapy. An increased risk of bleomycin pulmonary toxicity has been reported with G-CSF use for this disease in a retrospective study on 141 patients. 31 In a systematic review of case reports by Azoulay and colleagues, 37 70 cases of G-CSF-related pulmonary toxicity was identified in cancer patients with neutropenia. 36 patients had received bleomycin, but the majority of these were non-Hodgkin's lymphoma patients who have also received drugs known to induce pulmonary toxicity (cyclophosphamide and/or methotrexate). Of note, this possible risk of increased pulmonary toxicity was not seen with bleomycincontaining testicular cancer chemotherapy. 18 Evens et al 38 showed that standard chemotherapy for Hodgkin's lymphoma (ABVD) can be safely administered at full dose without G-CSF support. However, this requires treatment with ABVD in some patients at the time of neutropenia. Until further evidence from larger prospective studies becomes available, prophylactic G-CSF use with ABVD can be considered after discussion of risks and benefits with the patient.
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Patient Risk Factors for Developing FN (MGF-B)
As previously mentioned, patient risk factors are an important consideration in estimating the overall risk of FN, particularly when chemotherapy regimens are considered an intermediate risk (reviewed by Lyman et al 39 ). Patient factors may elevate the overall risk to a high risk category, where prophylactic CSFs are more routinely recommended. For example, many regimens for breast and lung cancer are associated with an intermediate risk of neutropenic complications, and it is important to identify which of these patients would be considered at high risk. Higher age, notably over 65 years, is the most important risk factor for developing severe neutropenia (see NCCN Senior Adult Oncology Guidelines). [40] [41] [42] [43] [44] [45] Other risk factors include previous chemotherapy or radiotherapy, pre-existing neutropenia or tumor involvement in the bone marrow, poor performance status, comorbidities including renal or liver dysfunction, and pre-existing conditions such as neutropenia and infection.
Therapeutic Use of CSFs (MGF-3)
Compared to prophylactic use, there is less evidence supporting therapeutic use of CSFs for FN as an adjunctive to antibiotics. In a Cochrane meta-analysis including 1518 patients from 13 trials 46 , Clark and colleagues reported a shorter length of hospitalization (HR = 0.63; 95% CI, 0.49 to 0.82; P = 0.0006), shorter time to neutrophil recovery (HR = 0.32; 95% CI, 0.23 to 0.46; P < 0.00001), but no improvement in overall survival associated with therapeutic CSF. An earlier metaanalysis by Berghmans et al 47 again found no difference in mortality, but they were unable to assess other clinical benefits. Of note, Berghmans' analysis did not include a multicenter trial that randomized 210 patients with solid tumors who developed chemotherapy-induced FN and had at least one high-risk factor to therapeutic G-CSF or placebo. 48 The G-CSF arm showed a significantly shorter duration of grade 4 neutropenia (median 2 vs. 3 days, P = 0.0004), antibiotic therapy (median 5 vs. 6 days, P = 0.013) and hospital stay (median 5 vs. 7 days, P = 0.015).
Patients with FN who are receiving prophylactic filgrastim or sargramostim should continue with CSF therapy. However, since pegfilgrastim is long-acting, those who have received prophylactic pegfilgrastim should not be treated with additional CSF. 49 Also, as there is currently a lack of evidence for therapeutic use of pegfilgrastim, only filgrastim or sargramostim should be administered in the therapeutic setting. For patients who have not received prophylactic CSFs, the NCCN panel recommends an evaluation for risk factors for infectionrelated complications or poor clinical outcome. These include: old age (> 65 years), sepsis syndrome, severe (ANC < 100/mcl) or anticipated 
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Dosing and Administration
Currently used myeloid growth factors for the prophylaxis of FN and maintenance of scheduled dose delivery include filgrastim, pegfilgrastim and sargramostim. While data from randomized studies support the use of filgrastim and pegfilgrastim in patients with solid malignancies, randomized studies of sargramostim have focused on its use following induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. Therefore, when choosing among myeloid growth factors, filgrastim and pegfilgrastim are considered category 1 recommendations, while sargramostin is considered a category 2B recommendation.
Initial doses of filgrastim are initiated beginning within 1-3 days after completion of chemotherapy in a daily dose of 5 mcg/kg until post-nadir ANC recovery is to normal or near-normal ANC levels by laboratory standards. The dose may be rounded to the nearest vial size by institution-defined weight limits. There is also evidence to support use of pegfilgrastim 24 hours after completion of chemotherapy given every 3 weeks in one dose of 6 mg per cycle of treatment. 8, 50 There are insufficient data to support dose and schedule of weekly regimens or schedules less than 2 weeks and these cannot be recommended. Same day administration of filgrastim or pegfilgrastim (within 24 hours of chemotherapy) is not recommended. Studies of pegfilgrastim administration the same day as chemotherapy versus administration the day after chemotherapy have demonstrated increased incidence of FN and/or adverse events in breast cancer and lymphoma. [51] [52] [53] [54] Same day pegfilgrastim showed comparable benefit in one study of a regimen with low risk neutropenia, but in this setting pegfilgrastim would not be routinely indicated. 55 There is insufficient evidence from randomized trials to support a category 1 recommendation for sargramostim in nonmyeloid malignancies. Sargramostim is indicated for use following induction chemotherapy in older adult patients with AML. 56 Again, administration of sargramostim on the same day as chemotherapy is not recommended. The subcutaneous route is preferred for all three agents. There are no data to support alternative dosing schedules in intermediate and high risk patients. The NCCN Myeloid Growth Factors panel members do not routinely recommend use of prophylactic antibiotics in these settings. In addition, prophylactic use of CSFs in patients given concurrent chemotherapy and radiation is not recommended.
Severe Chronic Neutropenia
The NCCN Myeloid Growth Factors Guidelines is focused on chemotherapy-induced neutropenia in the cancer setting. Severe chronic neutropenia that requires G-CSF therapy is briefly discussed below. G-CSF is established as an effective treatment for cyclic, congenital and idiopathic neutropenia (types of severe chronic neutropenia), based a randomized control trial involving 123 patients. 57 In this study, daily treatment with subcutaneously administered G-CSF normalized neutrophils in most patients and prevented fever, mouth ulcers and infections. Subsequent observation studies show that patients with idiopathic and cyclic neutropenia generally respond to lowdose daily, alternate-day or thrice-per-week subcutaneous G-CSF (1-3 mcg/kg/day). Congenital neutropenia patients generally require somewhat higher doses (3-10 mcg/kg./day). All patients should have doses adjusted to maintain a blood neutrophil level in the normal or low normal range. Acute adverse effects include bone pain, arthralgias and myalgias which usually diminish in the first few weeks of treatment. The greatest concern is that patients with the diagnosis of severe congenital neutropenia, but not all patients with chronic neutropenia, are at risk of evolving to myelodysplasia and leukemia, with or without
